scholarly journals Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

Cell ◽  
2012 ◽  
Vol 149 (4) ◽  
pp. 780-794 ◽  
Author(s):  
Michael J. Lee ◽  
Albert S. Ye ◽  
Alexandra K. Gardino ◽  
Anne Margriet Heijink ◽  
Peter K. Sorger ◽  
...  
2018 ◽  
Author(s):  
Dustin Lane

Programmed cell death signaling networks are frequently activated to coordinate the process of cell differentiation, and a variety of apoptotic events can mediate the process. This can include the ligation of death receptors, the activation of downstream caspases, and the induction of chromatin fragmentation, and all of these events can occur without downstream induction of death. Importantly, regulators of programmed cell death also have established roles in mediating differentiation. This review will provide an overview of apoptosis and its regulation by Inhibitors of Apoptosis (IAPs) and Bcl-2 family members. It will then outline the cross-talk between NF-ĸB and apoptotic signaling in the regulation of apoptosis before discussing the function of these regulators in the control of cell differentiation. It will end on a discussion of how a DNA damage-directed, cell cycle-dependent differentiation program may be controlled across multiple passages through cell cycle, and will assert that the failure to properly differentiate is the underlying cause of cancer.


2019 ◽  
Vol 17 (4) ◽  
pp. 20-26
Author(s):  
M. P. Kiseleva ◽  
V. S. Pokrovsky ◽  
V. V. Tataskiy ◽  
L. M. Borisova ◽  
I. S. Golubeva ◽  
...  

The paper discusses the possible mechanisms of antitumor action of indolocarbazole derivatives. Here we present a data that show interaction drugs based on indolocarbazole derivatives with several intracellular targets and consequently activation different pathways of cell death. Also we present results of our studies on the mechanisms of antitumor action of compounds LCS-1006 and LCS-1208 synthesized in the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia.


1990 ◽  
Vol 40 (10) ◽  
pp. 2353-2362 ◽  
Author(s):  
Michael A. Barry ◽  
Catherine A. Behnke ◽  
Alan Eastman

Toxicology ◽  
2019 ◽  
Vol 425 ◽  
pp. 152252 ◽  
Author(s):  
Cheng-Chin Huang ◽  
Chun-Ying Kuo ◽  
Ching-Yao Yang ◽  
Jui-Ming Liu ◽  
Ren-Jun Hsu ◽  
...  

Blood ◽  
1997 ◽  
Vol 90 (8) ◽  
pp. 3118-3129 ◽  
Author(s):  
Marek Los ◽  
Ingrid Herr ◽  
Claudia Friesen ◽  
Simone Fulda ◽  
Klaus Schulze-Osthoff ◽  
...  

Abstract The cytotoxic effect of anticancer drugs has been shown to involve induction of apoptosis. We report here that tumor cells resistant to CD95 (APO-1/Fas) -mediated apoptosis were cross-resistant to apoptosis-induced by anticancer drugs. Apoptosis induced in tumor cells by cytarabine, doxorubicin, and methotrexate required the activation of ICE/Ced-3 proteases (caspases), similarly to the CD95 system. After drug treatment, a strong increase of caspase activity was found that preceded cell death. Drug-induced activation of caspases was also found in ex vivo-derived T-cell leukemia cells. Resistance to cell death was conferred by a peptide caspase inhibitor and CrmA, a poxvirus-derived serpin. The peptide inhibitor was effective even if added several hours after drug treatment, indicating a direct involvement of caspases in the execution and not in the trigger phase of drug action. Drug-induced apoptosis was also strongly inhibited by antisense approaches targeting caspase-1 and -3, indicating that several members of this protease family were involved. CD95-resistant cell lines that failed to activate caspases upon CD95 triggering were cross-resistant to drug-mediated apoptosis. Our data strongly support the concept that sensitivity for drug-induced cell death depends on intact apoptosis pathways leading to activation of caspases. The identification of defects in caspase activation may provide molecular targets to overcome drug resistance in tumor cells.


Metallomics ◽  
2017 ◽  
Vol 9 (7) ◽  
pp. 891-901 ◽  
Author(s):  
Ignacio E. León ◽  
Paula Díez ◽  
Enrique J. Baran ◽  
Susana B. Etcheverry ◽  
Manuel Fuentes

Vanadium compounds were studied in recent years by considering them as a representative of a new class of non-platinum metal anticancer drugs.


2021 ◽  
Vol 31 (9) ◽  
pp. 093103
Author(s):  
Zhiyong Yin ◽  
Pei-pei Zhang ◽  
Fei Xu ◽  
Zhilong Liu ◽  
Ligang Zhu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document